The shift from fee-based to value-based medicine is placing new financial pressures on healthcare executives. Relying on traditional cost/benefit calculations when making capital purchases often falls short in achieving desired budget, revenue, and quality improvement goals.
That’s why many industry leaders are discovering the benefits of introducing clinical evidence into the capital planning process. Download this white paper, written by Winifred Hayes, Founder of Hayes Inc., and Bill Donato, General Manager of TractManager’s MD Buyline division. It’s the first in a series intended to help healthcare providers foster a more collaborative, informed, and strategic decision-making culture.